M. Tidwell

发表

Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-BD-Arabinofuranosylcytosine andMitoxantrone in Relapsed and RefractoryAdult Acute Leukemias

A. Passaniti, B. Smith, J. Karp, 2005 .

Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-d-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias

A. Passaniti, B. Smith, J. Karp, 2005, Clinical Cancer Research.

Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial.

J. Karp, J. Greer, J. Wright, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.

E. Sausville, J. Karp, J. Trepel, 2007, Blood.

Tertiary center referral patterns for patients with myelodysplastic syndrome are indicative of age and race disparities: a single-institution experience

Y. Ning, M. Tidwell, M. Baer, 2013, Leukemia & lymphoma.

Racial differences in presentation, referral and treatment patterns and survival in adult patients with acute myeloid leukemia: a single-institution experience.

Y. Ning, I. Gojo, M. Tidwell, 2012, Leukemia research.

Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine

M. Tidwell, M. Baer, B. Bhatnagar, 2015, Leukemia & lymphoma.

Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia

J. Karp, J. Greer, M. Levis, 2012, Leukemia & lymphoma.

Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy

E. Sausville, I. Gojo, M. Tidwell, 2011, Leukemia & lymphoma.

inhibitor, in adults with refractory and relapsed acute leukemias Phase 1 and pharmacologic study of MS-275, a histone deacetylase

J. Karp, J. Trepel, A. Sparreboom, 2013 .

Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy

E. Sausville, Y. Ning, Ching Chen, 2014, Leukemia & lymphoma.

High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication.

Y. Ning, Ching Chen, M. Tidwell, 2014, Cancer genetics.

Lack of Response of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) to Decitabine After Failure of Azacitidine

Y. Ning, M. Tidwell, M. Baer, 2012 .

Phase I Trial of Vorinostat Combined with Cytarabine and Etoposide in Patients (pts) with Advanced Acute Leukemia and High-Risk Myelodysplastic Syndromes

M. Tan, M. Egorin, I. Gojo, 2008 .

Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.

M. Sznol, J. Karp, J. Greer, 2007, Leukemia research.

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

J. Karp, S. Kaufmann, J. Wright, 2001, Blood.

Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias

D. Qian, J. Karp, Helen H. W. Chen, 2004, Clinical Cancer Research.

Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells.

J. Karp, M. Tidwell, A. Rapoport, 2004, Blood cells, molecules & diseases.

Treatment of catheter-related deep vein thrombosis in patients with acute leukemia with anticoagulation

E. Sausville, M. Tidwell, F. Kamangar, 2015, Leukemia & lymphoma.

Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide.

J. Karp, J. Bolaños-Meade, M. Tidwell, 2003, Leukemia research.

Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome

E. Sausville, M. Carroll, I. Gojo, 2013, Investigational New Drugs.